美國血液技術 HAE 深 滬
已收盤 08-29 16:00:00 美东时间
54.54
+0.200
+0.37%
華盛通- 最 高55.1202
- 今 開54.29
- 成交量 82.64万股
- 最 低 54.02
- 昨 收 54.34
- 總市值 26.20亿
- 52周最高 94.985
- 市盈率 靜 16.50
- 換手率 1.72%
- 52周最低 50.68
- 委 比 0.00%
- 總股本 4804.12万
- 歷史最高 142.11
- 量 比 1.05
- 振 幅 2.02%
- 歷史最低 25.98
- 每 手 1
- 風險率 8.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多What's Going On With Takeda Stock On Friday?
Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to Takeda's Takhzyro.
08-22 23:21
FDA Approves Ionis' DAWNZERA As First RNA-Targeted Therapy For Hereditary Angioedema, Offering Longest Dosing Option With Q4W Or Q8W Administration
- DAWNZERA demonstrated significant and sustained HAE attack rate reduction and long-term disease control -- Offers longest dosing option for HAE, with dosing every 4 or 8 weeks -- Compelling profile supported by
08-21 23:46
JP Morgan Downgrades Haemonetics to Neutral, Lowers Price Target to $62
JP Morgan analyst Rohin Patel downgrades Haemonetics (NYSE:HAE) from Overweight to Neutral and lowers the price target from $85 to $62.
08-08 18:37
美股大行评级 | DoorDash获上调目标价从230美元升至300美元； 摩根大通上调Shopify目标价从115美元升至179美元
今日重点评级关注：HC Wainwright & Co.：维持FibroGen"买入"评级，目标价从10美元升至43美元；摩根大通：维持Cogent Biosciences"超配"评级，目标价从29美元升至30美元
08-08 09:34
Haemonetics Affirms FY2026 Adj EPS Guidance of $4.70-$5.00 vs $4.87 Est
Haemonetics (NYSE:HAE) affirms FY2026 Adj EPS guidance from $4.70-$5.00 to $4.70-$5.00 vs $4.87 analyst estimate..
08-07 18:05
Haemonetics Q1 Adj. EPS $1.10 Beats $1.02 Estimate, Sales $321.394M Beat $305.115M Estimate
Haemonetics (NYSE:HAE) reported quarterly earnings of $1.10 per share which beat the analyst consensus estimate of $1.02 by 7.95 percent. This is a 7.84 percent increase over earnings of $1.02 per share from the same
08-07 18:02
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Earnings Preview: Dentsply Sirona
Dentsply Sirona (NASDAQ:XRAY) is gearing up to announce its quarterly earnings ...
08-07 01:06
Peering Into Haemonetics's Recent Short Interest
Haemonetics's (NYSE:HAE) short percent of float has fallen 4.44% since its last...
08-07 01:00
Astria Therapeutics Licenses D&C Rights In Japan To Kaken Pharma For Navenibart In Phase 3 Development For Preventative Treatment Of HAE; Astria To Receive $16M Upfront, With Potential For $16M In Commercialization Milestones
-- Up to $32 Million in Upfront and Milestone Payments, Plus Royalties ---- Kaken Expertise in Commercializing Innovative Therapies Supports Navenibart's Potential to be First-Choice HAE Treatment in Japan ---- Updated
08-06 20:17
